A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.

@article{Ghali2007AP1,
  title={A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.},
  author={Jalal K. Ghali and William Brit Smith and Guillermo Torre-Amione and William Haynos and Barry K Rayburn and Antonino Amato and Dan Zhang and Doug Cowart and Giovanni Sambin-Silvio Valentini and Paolo Carminati and Mihai Gheorghiade},
  journal={The American journal of cardiology},
  year={2007},
  volume={99 2A},
  pages={47A-56A}
}
Istaroxime (PST2744) is a luso-inotrope that stimulates the sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a without chronotropic effects. Additionally, it has beneficial effects on myocardial energetics. This phase 1-2 clinical trial in patients with chronic stable heart failure (HF) is the first evaluation of istaroxime in humans. Three cohorts of 6 patients each were exposed to 4 sequentially increasing 1-hour infusions with a random placebo. Doses were 0.005-5.0 micro/kg… CONTINUE READING